• In May 2026, Humana’s CenterWell Pharmacy began full operations at an US$83 million, 162,000-square-foot mail-order distribution center in Orlando, Florida, capable of handling up to 64,000 prescriptions per day and employing more than 165 specialists.
• The new Orlando facility expands CenterWell Pharmacy’s national fulfillment network, supporting payer-agnostic partnerships and free pharmacy technician training that could deepen Humana’s role in medication access and workforce development.
• We’ll now examine how this expanded CenterWell Pharmacy capacity in Orlando reshapes Humana’s existing investment narrative around growth and efficiency.

We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Humana Investment Narrative Recap

To own Humana, you need to believe its Medicare Advantage core can stay resilient while CenterWell deepens its role in care delivery and pharmacy services. The new US$83 million Orlando mail-order hub may modestly support near term efficiency and growth, but it does not directly change the most important short term catalyst around Stars quality performance or the key risk tied to regulatory and reimbursement uncertainty.

The Orlando facility sits squarely within the CenterWell expansion catalyst, where growth in value based models and specialty pharmacy is already a focus. It connects with Humana’s broader push to improve clinical excellence and member experience, including recent partnerships such as the b.well Connected Health integration that aims to streamline data access and support more coordinated care, potentially reinforcing the case for CenterWell as a driver of membership and service revenue growth.

Yet, against this operational progress, there remains a material Stars, reimbursement and regulatory risk profile that investors should be aware of...

Humana's narrative projects $184.2 billion revenue and $3.1 billion earnings by 2029.

Uncover how Humana's forecasts yield a $210.46 fair value, a 40% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming only about US$129.7 billion of revenue and US$2.4 billion of earnings by 2028, so compared with the Orlando expansion and the more optimistic views on CenterWell’s role, you can see how much more cautious they are, and why it is worth weighing these very different expectations side by side.

Explore 5 other fair value estimates on Humana - why the stock might be worth 40% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Humana research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.